Mitrix Bio wants to sell you new batteries for your cells.

Here is a fact about your body that is both boring and, if you sit with it, slightly alarming: every cell you own runs on tiny power plants called mitochondria, and over the decades those power plants get worse at their job. The batteries wear down. This is not a metaphor for aging so much as a candidate for its actual mechanism. Mitrix Bio, an 11-person startup based in the East Bay, has decided to take that candidate seriously and do the obvious, deeply non-trivial thing: grow fresh mitochondria in a tank and put them into people.

The obvious-but-hard framing is the whole story here, so it is worth being precise. The idea is not new. Researchers have moved mitochondria between cells for years, and hospitals have used a version of it in specific surgical settings. What Mitrix is attempting is the manufacturing problem sitting underneath the idea - how do you make a lot of young, functional mitochondria, reliably, and get them to survive being injected into a person? That is a factory question dressed up as a biology question, which is roughly the kind of question you would expect from the company's founder.

The founder came from a particle accelerator

Tom Benson did not arrive from a conventional biotech track. Before Mitrix, he was a serial founder of software, hardware and science startups, and - the detail that makes the whole thing legible - he managed the Linac Coherent Light Source, the femtosecond free-electron laser at SLAC, Stanford's linear accelerator lab. That is a machine that images matter at almost unimaginably small scales. Benson has said his interest in mitochondria grew out of imaging them via X-ray crystallography and Cryo-EM. Which is to say: a person who spent his days measuring very small things very precisely looked at the very small things inside your cells and decided the interesting move was to manufacture them.

This is a useful lens for reading Mitrix. It is not, at heart, a company built around a single molecular discovery. It is a company built around a production process. Benson's stated ambition is to make bioreactor-grown mitochondria "on an industrial scale" - a toolkit of many different mitochondria types that clinicians could draw on to regenerate different organs. The comparison he keeps reaching for is not a drug. It is infrastructure.

What, exactly, is a Mitlet?

Every good deep-tech company eventually needs a word that a non-scientist can picture, and Mitrix has one: Mitlets. A Mitlet is a young, bioreactor-grown mitochondrion wrapped in a vesicle - an exosome-like membrane bubble - so that a target cell will actually take it up rather than ignore it. You can think of it as a battery that ships in its own delivery packaging. The naming is almost suspiciously good marketing for a research-stage biotech: "little mitochondria" is exactly what they are.

The autologous part matters. Because the mitochondria are grown from the patient's own stem cells and returned to that same patient, Mitrix sidesteps a lot of the immune-rejection problem that haunts donor-based cell therapies. The company has described expected results in the range of a 2-10% increase in functional mitochondrial abundance - modest-sounding numbers that, in mitochondrial terms, its founder frames as a meaningful boost to muscle function, immunity and cognition. (Figures are the company's own projections, not peer-reviewed clinical outcomes.)

The money is small. The claim is not.

In January 2021, Mitrix announced $250,000 in pre-seed funding for what it then described as a "whole-body mitochondrial transfusion." The check was split evenly between Ronjon Nag's R42 AI and Longevity Fund and Petr Sramek's Longevity Tech Fund. Two hundred and fifty thousand dollars is, by biotech standards, a rounding error - the kind of sum that funds a serious seed deck and some early lab work, not a pipeline. And yet the goal attached to it is to eventually supplement the mitochondria of every human being over the age of 55.

There is a temptation to read that gap as a red flag, and in the longevity field - which has a genuine, self-acknowledged hype problem - skepticism is the correct default setting. But the gap between a tiny raise and a huge ambition is also just what an early frontier company looks like before anyone has decided it is real. The honest way to hold Mitrix is as an experiment in progress: interesting, unproven, and refreshingly specific about what it is trying to do.

The academic company it keeps

A pre-seed startup making claims this large lives or dies on credibility-by-association, and Mitrix has assembled a respectable bench. Its advisors and collaborators have included Stanford's Dr. Michael Snyder and, on the regenerative side, Dr. Thomas Rando, plus working researchers at the University of Kentucky (Alexander Rabchevsky, Patrick Sullivan, Samirkumar Patel) and the University of Manitoba (Benedict Albensi). By 2025, the collaborator list around its human work had grown to include Stanford, UCLA and New York's Northwell Health. None of this proves the therapy works. It does suggest that serious people are willing to be in the room.

A 90-year-old physicist goes first

In mid-2025, Mitrix moved from theory toward the clinic. It announced a volunteer mitochondrial transplantation effort, with a trial slated to begin August 1, 2025, seeking up to five more participants aged 55 and older or living with chronic conditions. The first volunteer is John G. Cramer, a 90-year-old emeritus physics professor at the University of Washington - a man who, outside the lab, is also known as a science-fiction writer, which is either poetic or on-the-nose depending on your mood.

A first-in-human volunteer study is not an efficacy trial, and it is worth saying plainly that we do not yet know whether any of this extends a healthy life by a single day. Mitrix has been open about a long road: pre-clinical animal work, a safety-first commercialization strategy that includes proving safety in Japan before generating efficacy data, and a general availability estimate measured in the neighborhood of fifteen years. In an industry where "coming soon" is a genre, that timeline is at least admirably unglamorous.

The timeline so far

So what can you actually do with it?

Right now, honestly, nothing - and that is the correct answer for a research-stage company. There is no product to buy, no clinic to visit. What Mitrix offers today is a thesis you can evaluate and a set of experiments you can follow. If the science holds, the eventual pitch is straightforward: for people over 55 or managing chronic disease, a periodic top-up of young, self-derived mitochondria aimed at restoring cellular energy - and, downstream, muscle, immune and cognitive function. The founder has floated applications beyond aging too, from genetic disease to stroke recovery. Those are hopes, not features. But they are legible hopes, and legibility is rarer in this field than it should be.

The tidy way to summarize Mitrix Bio is that it took a widely accepted observation - mitochondria decline with age - and treated it as a manufacturing spec rather than a fact of life. Whether that turns into medicine is genuinely unknown, and anyone telling you otherwise is selling something. But as bets go, "make new batteries for the cell and see what happens" is a clear one. You can watch it succeed or fail on its own terms, which is more than you can say for most companies promising to add years to your life.